Xcout IntelNaurex
Naurex was a biopharmaceutical company that developed novel therapeutics targeting the NMDA receptor, including the antidepressant candidate GLYX-13 (rapastinel). It was acquired…
The full profile of Naurex
Funding, investors, leadership and board, hiring signals, tech stack and corporate events for this company are available inside Xcout Intel. Subscribe to open it.
Subscribe to see Naurex →Already a subscriber? Sign in
Xcout Intel tracks Naurex continuously — this profile deepens as new filings, funding, people and hiring data arrive.